drugset / Trial / NCT02469974
Ruxolitinib in Combination With Autotransplant
NaSingle-groupOpen-labelTreatment
Summary
To determine the safety of the approach of giving RUXOLITINIB before and after an autologous stem cell transplant, as measured by graft failure or death.
Timeline
- Start
- 2015-05
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 5 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |
| Background | Busulfan | Small molecule | 2 mg/kg | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 10 ug/kg | Intravenous |